

Echocardiographic Evaluation of AV Hemodynamics and Morphology

Jong-Min Song

*Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea*

Aortic Stenosis

○ Etiology

● Congenital

➤ **Bicuspid**

● Acquired

➤ **Degenerative**

- Calcium deposition
- AR : rare
- DM, hypercholesterolemia
- Smoking, HT, low HDL

➤ **Rheumatic**

- Commissure fusion
- Cusp retraction & stiffening
- MV involvement
- AR : common



Bicuspid AS

FR 39Hz
14cm
2D
56%
C 50
P Low
HGen

P 1.7 R 3.4



JPEG

84 bpm

M3
FR 39Hz
11cm
2D
55%
C 50
P Low
HGen

P 1.7 R 3.4



JPEG

80 bpm



Degenerative AS

FR 39Hz
14cm
2D
58%
C 48
P Low
HGen

P R
1.7 3.4

M3 FR 39Hz
11cm
2D
52%
C 48
P Low
HGen

P R
1.7 3.4

M3

JPEG

74 bpm

JPEG

73 bpm

Rheumatic AS

FR 39Hz
14cm
2D
53%
C 50
P Low
HGen




JPEG
76 bpm

M3
FR 39Hz
8.5cm
2D
53%
C 50
P Low
HGen



JPEG
77 bpm

Hemodynamics




FR 20Hz
18cm

2D
61%
C 48
P Low
HGen
CF
74%
2.5MHz
WF High
Med




C 50
P Low
HGen
CF
70%
2.5MHz
WF Low
Med




Measurement of AVA

CONTINUITY EQUATION USED TO DETERMINE AORTIC VALVE AREA



AVA by Continuity Equation



AVA by TEE Planimetry

FR 53Hz
8.5cm

2D
63%
C 50
P Off
Gen



G
P R

PAT T: 37.0C
TEE T: 39.1C

M4
FR 54Hz
8.5cm

2D
67%
C 50
P Off
Gen




G
P R

83 bpm
Area 0.442 cm²

82bpm

Asymptomatic Severe AS

Event-free survival



— $V_{max} < 3.0 \text{ m/s}$

— $V_{max} = 3.0-4.0 \text{ m/s}$

— $V_{max} > 4.0 \text{ m/s}$



Otto et al. Circulation 1997;95:2262-70

Stages of AS



Table 8. Stages of Valvular AS

Stage	Definition	Valve Anatomy	Valve Hemodynamics	Hemodynamic Consequences	Symptoms
A	At risk of AS	<ul style="list-style-type: none"> Bicuspid aortic valve (or other congenital valve anomaly) Aortic valve sclerosis 	<ul style="list-style-type: none"> Aortic $V_{max} < 2$ m/s 	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> None
B	Progressive AS	<ul style="list-style-type: none"> Mild-to-moderate leaflet calcification of a bicuspid or trileaflet valve with some reduction in systolic motion or Rheumatic valve changes with commissural fusion 	<ul style="list-style-type: none"> Mild AS: Aortic V_{max} 2.0–2.9 m/s or mean $\Delta P < 20$ mm Hg Moderate AS: Aortic V_{max} 3.0–3.9 m/s or mean ΔP 20–39 mm Hg 	<ul style="list-style-type: none"> Early LV diastolic dysfunction may be present Normal LVEF 	<ul style="list-style-type: none"> None
C: Asymptomatic severe AS					
C1	Asymptomatic severe AS	<ul style="list-style-type: none"> Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening 	<ul style="list-style-type: none"> Aortic $V_{max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg AVA typically is ≤ 1.0 cm² (or AVAi ≤ 0.6 cm²/m²) Very severe AS is an aortic $V_{max} \geq 5$ m/s or mean $\Delta P \geq 60$ mm Hg 	<ul style="list-style-type: none"> LV diastolic dysfunction Mild LV hypertrophy Normal LVEF 	<ul style="list-style-type: none"> None: Exercise testing is reasonable to confirm symptom status
C2	Asymptomatic severe AS with LV dysfunction	<ul style="list-style-type: none"> Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening 	<ul style="list-style-type: none"> Aortic $V_{max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg AVA typically ≤ 1.0 cm² (or AVAi ≤ 0.6 cm²/m²) 	<ul style="list-style-type: none"> LVEF $< 50\%$ 	<ul style="list-style-type: none"> None
D: Symptomatic severe AS					
D1	Symptomatic severe high-gradient AS	<ul style="list-style-type: none"> Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening 	<ul style="list-style-type: none"> Aortic $V_{max} \geq 4$ m/s or mean $\Delta P \geq 40$ mm Hg AVA typically ≤ 1.0 cm² (or AVAi ≤ 0.6 cm²/m²) but may be larger with mixed AS/AR 	<ul style="list-style-type: none"> LV diastolic dysfunction LV hypertrophy Pulmonary hypertension may be present 	<ul style="list-style-type: none"> Exertional dyspnea or decreased exercise tolerance Exertional angina Exertional syncope or presyncope
D2	Symptomatic severe low-flow/low-gradient AS with reduced LVEF	<ul style="list-style-type: none"> Severe leaflet calcification with severely reduced leaflet motion 	<ul style="list-style-type: none"> AVA ≤ 1.0 cm² with resting aortic $V_{max} < 4$ m/s or mean $\Delta P < 40$ mm Hg Dobutamine stress echocardiography shows AVA ≤ 1.0 cm² with $V_{max} \geq 4$ m/s at any flow rate 	<ul style="list-style-type: none"> LV diastolic dysfunction LV hypertrophy LVEF $< 50\%$ 	<ul style="list-style-type: none"> HF Angina Syncope or presyncope
D3	Symptomatic severe low-gradient	<ul style="list-style-type: none"> Severe leaflet calcification 	<ul style="list-style-type: none"> AVA ≤ 1.0 cm² with aortic $V_{max} < 4$ m/s or 	<ul style="list-style-type: none"> Increased LV 	<ul style="list-style-type: none"> HF

2014 AHA/ACC Guideline

Very Severe AS

- **116 consecutive asymptomatic patients with very severe isolated AS (AV-Vel > 5.0 m/s)**




Patients with AV-Vel from 4.0 to 5.0 m/s				
Pts. at risk:	82	69	59	38
Patients with AV-Vel from 5.0 to 5.5 m/s				
Pts. at risk:	72	53	29	18
Patients with AV-Vel ≥ 5.5 m/s				
Pts. at risk:	44	20	11	5

Circulation. 2010;121:151-156


Asymptomatic Very Severe AS

AVA \leq 0.75 cm² &
(Vmax \geq 4.5 m/s or
mean PG \geq 50 mm Hg)



No at Risk

OP	102	96	48	29
CONV	95	82	54	32




No at Risk


OP	102	96	48	29
CONV	95	82	54	32

Kang DH, Circulation. 2010 ;121:1502-9.

Asymptomatic Very Severe AS




Female	47	34	22
Male	44	35	20
			9



No at Risk

<5.0m/s	53	37	23
≥5.0m/s	32	29	17
			9



Kang DH, Circulation. 2010 ;121:1502-9.

Timing of Intervention for AS


Table 9. Summary of Recommendations for AS: Timing of Intervention

Recommendations	COR	LOE	References
AVR is recommended with severe high-gradient AS who have symptoms by history or on exercise testing (stage D1)	I	B	(9, 91, 134, 135)
AVR is recommended for asymptomatic patients with severe AS (stage C2) and LVEF <50%	I	B	(136, 137)
AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery	I	B	(108, 138)
AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic velocity ≥ 5.0 m/s) and low surgical risk	IIa	B	(139, 140)
AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise tolerance or an exercise fall in BP	IIa	B	(25, 47)
AVR is reasonable in symptomatic patients with low-flow/low-gradient severe AS with reduced LVEF (stage D2) with a low-dose dobutamine stress study that shows an aortic velocity ≥ 4.0 m/s (or mean pressure gradient ≥ 40 mm Hg) with a valve area ≤ 1.0 cm ² at any dobutamine dose	IIa	B	(43, 141, 142)
AVR is reasonable in symptomatic patients who have low-flow/low-gradient severe AS (stage D3) who are normotensive and have an LVEF $\geq 50\%$ if clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms	IIa	C	N/A
AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are undergoing other cardiac surgery	IIa	C	N/A
AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease progression and low surgical risk	IIb	C	N/A

AS indicates aortic stenosis; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; COR, Class of Recommendation; LOE, Level of Evidence; LVEF, left ventricular ejection fraction; and N/A, not applicable.


2014 AHA/ACC Guideline

Tight AS with Severe LV dysfunction




deFilippi et al. Am J Cardiol 1995;75:191-195

Tight AS with Severe LV dysfunction



Nishimura et al. Circulation 2002;106:809-813

Asymptomatic Severe AS




NO. OF PATIENTS AT RISK

No or mild calcification	25	23	20	17	9
Moderate or severe calcification	101	48	38	21	7


N Engl J Med 2000;343:611-7

Asymptomatic Severe AS



N Engl J Med 2000;343:611-7

Asymptomatic Severe AS



No. OF PATIENTS AT RISK

34




12

7

5


N Engl J Med 2000;343:611-7

Aortic Valve Annulus



Circ Cardiovasc Intervent. 2008;1:74-81



Measurement of Aortic Annulus Size



The mean difference (TTE-TEE) is -1.36 mm (2 SD -4.48 to +1.75 mm).

Moss, JACC Img 2008;1:15-24

TTE, TEE & CT



JACC 2010;55:186-94

TTE, TEE & CT

Table 1 Comparison Between Echocardiographic and MSCT Measurements



	Mean Annulus Diameter (mm)	Median	Range	p Value vs. TTE	R vs. TTE	p Value vs. TEE	R vs. TEE
Echocardiographic measurements							
TTE	23.9 ± 2.1	24	19-30	—	—	0.13	0.89
TEE	24.1 ± 2.1	24.5	20-30	0.13	0.89	—	—
MSCT measurements							
Virtual basal ring							
Long-axis	27.5 ± 3.1	27	22-34	<0.0001	0.69	<0.0001	0.67
Short-axis	21.7 ± 2.3	22	17.5-28	<0.0001	0.73	<0.0001	0.69
Mean	24.6 ± 2.4	24	19.8-29.5	0.004	0.80	0.07	0.77
3-chamber view	23.8 ± 2.6	24	18-29	0.73	0.71	0.26	0.70

Data presented are mean ± SD. R is coefficient of correlation.



MSCT = multislice computed tomography; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography.

JACC 2010;55:186-94



TTE, TEE & CT



P= 0.13; mean difference, **0.22 mm**
limits of agreement, -1.73 to 2.16






P= 0.73; mean difference, **0.10 mm**
limits of agreement, -3.76 to 3.57



P=0.26; mean difference, **0.32 mm**
limits of agreement, -4.03 to 3.40

JACC 2010;55:186-94

Measurement of Aortic Valve Annulus



Circ Cardiovasc Intervent. 2008;1:74-81



Biplane Image

FR 28Hz
11cm

0:06:01

M4

xPlane
66%
66%
50dB
P Off
Gen



Dist 2.38 cm

73bpm

AV on 3D TEE

FR 28Hz
11cm

Live 3D
3D 42%
3D 40dB
Gen



M4




JPEG

50 bpm


PAT T: 37.0C
TEE T: 39.1C

Annulus Measurement by 3D TEE




JASE 2011;24:937-65

Annulus Measurement by 3D TEE



JASE 2013;26:359-69





CT & 2D-/3D-TEE



JACC 2013;61:908-16


CT & 2D-/3D-TEE

For predicting significant paravalvular AR



JACC 2013;61:908-16


Localization of LCA by 3D TEE



In general, a distance of **>10 mm** is desirable for the 23 mm balloon-expandable valve and a distance of **>11 mm** is desirable for the 26 mm valve.


JASE 2013;26:359-69

Post-Implantation




Moss, JACC Img 2008;1:15-24

Paravalvular AR After Implantation




Moss, JACC Img 2008;1:15-24

AR index & Prognosis



No. at risk

none/mild	124	120	77	49
moderate/severe	22	17	9	7
Total	146	137	86	56



No. at risk

AR index ≥ 25	96	92	62	35
AR index < 25	50	45	24	21
Total	146	137	86	56




Figure 1 Calculation of the AR Index

Simultaneous determination of left ventricular end-diastolic pressure (LVEDP) (blue line) and diastolic blood pressure (DBP) in the aorta (red line) in a patient without peri-prosthetic aortic regurgitation (periAR) (A) and in a patient with moderate periAR (B) for the calculation of the aortic regurgitation (AR) index: $([DBP - LVEDP]/SBP) \times 100$. (A) AR index = $([65 - 10]/160) \times 100 = 34.4$. (B) AR index = $([40 - 20]/130) \times 100 = 15.4$.

JACC 2012;59:1134-41

Severity of AR

Table 10 Prosthetic Valve Dysfunction


	Prosthetic Aortic Valve Stenosis ^a		
	Normal	Mild Stenosis	Moderate/Severe Stenosis
Quantitative parameters (flow-dependent)[†]			
Peak velocity (m/s)	<3 m/s	3–4 m/s	>4 m/s
Mean gradient (mmHg)	<20 mm Hg	20–40 mm Hg	>40 mm Hg
Quantitative parameters (flow-independent)			
Doppler velocity index [‡]	>0.35	0.35–0.25	<0.25
Effective orifice area [§]	>1.1 cm ²	1.1–0.8 cm ²	<0.8 cm ²
Effective orifice area	>0.9 cm ²	0.9–0.6 cm ²	<0.6 cm ²
	Prosthesis-Patient Mismatch (PPM)		
	Insignificant	Moderate	Severe
Indexed effective orifice area [¶] (cm ² /m ²)	>0.85 cm ² /m ²	0.85–0.65 cm ² /m ²	<0.65 cm ² /m ²
Indexed effective orifice area [#] (cm ² /m ²)	>0.70 cm ² /m ²	0.90–0.60 cm ² /m ²	<0.60 cm ² /m ²
	Prosthetic Aortic Valve Regurgitation		
	Mild	Moderate	Severe
Semi-quantitative parameters			
Diastolic flow reversal in the descending aorta—PW	Absent or brief early diastolic	Intermediate	Prominent, holodiastolic
Circumferential extent of prosthetic valve paravalvular regurgitation (%)**	<10%	10–29%	≥30%
Quantitative parameters[‡]			
Regurgitant volume (mL/beat)	<30 ml	30–59 ml	≥60 ml
Regurgitant fraction (%)	<30%	30–49%	≥50%
EROA (cm ²)	0.10 cm ²	0.10–0.29 cm ²	≥0.30 cm ²

*In conditions of normal or near normal stroke volume (50–70 ml). †These parameters are more affected by flow, including concomitant aortic regurgitation. ‡For LVOT >2.5 cm, significant stenosis criteria is <0.20. §Use in setting of BSA ≥1.6 cm² (note: dependent on the size of the valve and the size of the native annulus). ||Use in setting of BSA <1.6 cm². ¶Use in setting of BMI <30 kg/cm². #Use in setting of BMI ≥30 kg/cm². **Not well-validated and may overestimate the severity compared with the quantitative Doppler.

EROA = effective regurgitant orifice area; PW = pulsed wave.

JACC 2012;60:1438–54


Evaluation after TAVI



Mild Paravalvular Leakage

FR 14Hz
11cm

2D
70%
C 50
P Off
Gen
CF
53%
3.3MHz
WF High
Low




PAT T: 37.0C
TEE T: 39.5C

JPEG

63 bpm

Severe Paravalular Leakage



Thank you for your attention.

